You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

49 Results
Guidelines and Advice
Status: Current
ID: GL-C50-20
May 2015
Drug
Other Name(s): Provera® (multiple brands available)
Apr 2015
Guidelines and Advice
Jan 2015
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    chlorambucil
Dec 2018
Guidelines and Advice
Statistical Reports
Guidelines and Advice
Status: In-Review
ID: 19-4
May 2015
Guidelines and Advice
Jan 2015
Guidelines and Advice

Pages